FDA advisers back Gilead's cystic fibrosis drug

12/10/2009 | Reuters

An FDA panel recommended approval of Gilead Sciences' cystic fibrosis drug aztreonam to treat lung infections caused by common Pseudomonas aeruginosa bacteria in CF patients. The advisers found the treatment safe and effective when administered in 75-milligram doses three times daily.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC